SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
The Qualcomm Institute is launching a new innovation space at the University of California, San Diego with the capacity to house 15 to 20 seed-stage startups.
BIOTECH: Deal With Bayer May Be Worth Up to $375 Million
Isis Pharmaceuticals has landed a megadeal with aspirin-maker Bayer AG to move a potential blockbuster drug from the lab to the market.
BIOTECH: Bioprinter Aims to Give L’Oreal Tissue for Product Testing
Organovo has landed a research partnership with beauty conglomerate L’Oreal to create 3-D bioprinted human skin to test cosmetics.
In a deal potentially worth up to $1.3 billion, San Diego’s Sorrento Therapeutics has sold the rights to its proposed cancer treatment Cynviloq, as well as the wholly owned subsidiary that was developing the drug, to Illinois-based NantPharma.
San Diego drug developer Celladon Corp. said it is laying off half of its staff to cut costs after its lead gene therapy to treat heart failure failed a key trial last month.
San Diego’s research community has attracted a new Big Pharma partner. Sanford-Burnham Medical Research Institute will collaborate with Eli Lilly and Company to develop immunological therapies, the companies announced Thursday.
Scripps Health and Sharp Healthcare are joining San Diego Health Connect, a substantial boost for the region’s health information exchange that soon will give clinicians access to medical data covering 2.7 million county residents.
Medical device maker ResMed announced that a major clinical trial that sought to show its sleep therapy products protected heart failure patients actually slightly increased the risk of death.
San Diego’s Orexigen Therapeutics Inc. and its marketing partner Takeda Pharmaceutical Co. Ltd. on Tuesday abruptly terminated a study into how Orexigen’s Contrave obesity drug might affect the cardiovascular system.
Ligand Pharmaceuticals Inc. has spent $4 million to acquire a portfolio of more than 15 biologic development programs from Swiss biotech firm Selexis SA, which could provide future milestone and royalty payments.
San Diego-based Cidara Therapeutics Inc. has received fast-track designation from the U.S. Food and Drug Administration for its leading drug candidate for fungal infections.
San Diego-based Vical Inc. reported a net loss of $3.8 million for the first quarter of 2015, compared with a net loss of $3.5 million in the same quarter the previous year.
San Diego-based Acadia Pharmaceuticals Inc. reported a net loss of $40.4 million in the first quarter of 2015, more than double the net loss of $17.8 million during the same quarter last year.
HEALTH: Hospital In Rancho Mirage Is Also in Talks
UC San Diego Health System and the City of El Centro are entering into an agreement to expand health care services to Imperial Valley, the university announced.
BIOTECH: Device Can Rapidly Rule Out Cardiac Disease
The Tri-City Healthcare District Board of Directors has approved the purchase and installation of one of the most advanced computed tomography (CT) scanners on the market, enabling its radiologists to make quick and accurate diagnoses for patients.